However, the IL-1 superfamily also plays a critical role in host immunity, which might directly hamper the adoption of IL-1 blockers as potential treatments, as recent trials have raised concerns about the effects on non-cardiovascular events (such as infections or cancers) secondary to these drugs. The gene discussed is IL1A; the disease is cancer.